SCHEMBL6087293

SCHEMBL6087293

CC(=O)OCCNc1ccc2c(c1)CO/C2=C1/C(=O)Nc2ccccc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 1/20 0.38
CCNA2 P20248 1/20 0.38
CDK2 P24941 1/20 0.38
CCNA1 P78396 1/20 0.38
MAPT P10636 7/20 0.38
IDO1 P14902 2/20 0.36
TDO2 P48775 1/20 0.36
KDM4E B2RXH2 1/20 0.36
PGR P06401 6/20 0.35
NR3C1 P04150 5/20 0.35
NR3C2 P08235 4/20 0.35
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
HSD17B10 Q99714 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
APP P05067 1/20 0.34
THRB P10828 1/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
SNCA P37840 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6087297 1.00 NTRK1 (0.38) NTRK1CCNA2CDK2CCNA1MAPT
SCHEMBL6088048 0.90 MAPK14 (0.40) MAPTKDM4EPGRNR3C1NR3C2
SCHEMBL6088044 0.90 MAPK14 (0.40) MAPTKDM4EPGRNR3C1NR3C2
SCHEMBL6086573 0.88 PDGFRB (0.37) NTRK1CCNA2CDK2CCNA1MAPT
SCHEMBL6086570 0.88 IDO1 (0.35) NTRK1CCNA2CDK2CCNA1MAPT
SCHEMBL14725094 0.86 NTRK1 (0.36) NTRK1CCNA2CDK2CCNA1MAPT
SCHEMBL6086835 0.86 LMNA (0.37) NTRK1CCNA2CDK2CCNA1MAPT
SCHEMBL6086825 0.86 LMNA (0.37) NTRK1CCNA2CDK2CCNA1MAPT
SCHEMBL6088655 0.85 ALDH1A1 (0.38) NTRK1CCNA2CDK2CCNA1MAPT
SCHEMBL6088653 0.85 ALDH1A1 (0.38) NTRK1CCNA2CDK2CCNA1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490356-B1 (3Z)-3-(3-HYDRO-ISOBENZOFURAN-1-YLIDENE)-1,3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS ALLERGAN INC (US) 2013-02-27 EP disclosed
US-7060844-B2 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-06-13 US disclosed
US-20060004084-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-01-05 US disclosed
US-20040019098-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2004-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004084-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors CDK2, ERBB2, MAP3K3 NTRK1 408/4885CCNA2 406/4885CDK2 1/4885
US-20040019098-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors CDK2, ERBB2, MAP3K3 NTRK1 420/4885CCNA2 423/4885CDK2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.